Last reviewed · How we verify
Fatty Acids, Unsaturated
Unsaturated fatty acids modulate inflammatory pathways and cellular membrane composition to reduce cardiovascular and metabolic dysfunction.
Unsaturated fatty acids modulate inflammatory pathways and cellular membrane composition to reduce cardiovascular and metabolic dysfunction. Used for Hypertriglyceridemia, Cardiovascular disease prevention, Metabolic syndrome.
At a glance
| Generic name | Fatty Acids, Unsaturated |
|---|---|
| Also known as | OmegaRegen, Esters of Unsaturated Fatty Acids, EFA |
| Sponsor | Wroclaw Medical University |
| Drug class | Lipid therapeutic / Nutraceutical |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Unsaturated fatty acids, particularly omega-3 and omega-6 polyunsaturated fatty acids, integrate into cell membranes and serve as precursors for bioactive lipid mediators (e.g., prostaglandins, resolvins) that regulate inflammation and immune responses. They also improve lipid profiles, reduce triglycerides, and enhance endothelial function through multiple signaling pathways including GPR120 and PPAR activation.
Approved indications
- Hypertriglyceridemia
- Cardiovascular disease prevention
- Metabolic syndrome
Common side effects
- Gastrointestinal upset
- Fishy aftertaste
- Bleeding tendency (at high doses)
Key clinical trials
- Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell Disease (PHASE3)
- Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome (PHASE2)
- Anti-Inflammatory Effects of Pecan Nut Oil Supplementation in Adults With Overweight: A Randomized Controlled Parallel-Group Clinical Trial (NA)
- Combined Use of Oxytocin and Misoprostol in the Prevention of Post Partum Haemorrhage (PHASE4)
- 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients (PHASE4)
- AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension (PHASE1, PHASE2)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Qutenza 8% Capsaicin Topical System for the Treatment of Neuropathic Axial Lower Back Pain and Lumbosacral Radiculopathy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |